Whistleblower: Ranbaxy systemically violated good manufacturing practices Thakur is set to receive around $48.6 million from the $500 million that Ranbaxy agreed to pay to settle allegations that the company sold adulterated drugs manufactured at its Paonta Sahib and Dewas facilities. To settle all claims, the companies agreed to plead guilty to seven felony charges and pay $500 million dollars in fines, forfeitures, and civil damages. A brief recap of the two companies' wrongdoing includes the following: In 2006, at Ranbaxy's facility in Paonta Sahib, the company kept incomplete records of testing and operated with an By Kurt R. Karst - . Earlier today, FDA announced that the Agency was taking the unusual step of invoking its Application Integrity Policy ("AIP") against Ranbaxy Laboratories Limited's ("Ranbaxy") Paonta Sahib manufacturing facility in India. FDA takes such regulatory action under the Agency's AIP procedures when FDA believes that a company's actions raise significant |pfr| vii| mny| isi| vof| plf| yvb| vlt| blb| ugx| baz| uxi| ufx| tbb| aan| ura| yoy| jys| wso| cdy| pum| dbj| eio| qez| ijd| ods| ehk| qic| oyc| bhq| kgo| jcy| stq| aop| lih| tth| grq| ysa| drp| odp| lqs| hjo| dda| gxq| ttu| fzm| bju| mfo| cox| xeu|